Zhongli Cai

5.2k total citations · 1 hit paper
86 papers, 4.1k citations indexed

About

Zhongli Cai is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Zhongli Cai has authored 86 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Radiology, Nuclear Medicine and Imaging, 27 papers in Oncology and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Zhongli Cai's work include Radiopharmaceutical Chemistry and Applications (38 papers), Radiation Therapy and Dosimetry (18 papers) and Monoclonal and Polyclonal Antibodies Research (16 papers). Zhongli Cai is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (38 papers), Radiation Therapy and Dosimetry (18 papers) and Monoclonal and Polyclonal Antibodies Research (16 papers). Zhongli Cai collaborates with scholars based in Canada, United States and China. Zhongli Cai's co-authors include Raymond M. Reilly, Michael D. Sevilla, Xifeng Li, Jean‐Philippe Pignol, Niladri Chattopadhyay, Eli Lechtman, Pierre Cloutier, Darel J. Hunting, Léon Sanche and Conrad Chan and has published in prestigious journals such as Physical Review Letters, The Journal of Chemical Physics and Blood.

In The Last Decade

Zhongli Cai

84 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Auger electrons for cancer therapy – a review

2019 379 citations Zhongli Cai, Raymond M. Reilly et al. EJNMMI Radiopharmacy and Chemistry profile →

Peers

Countries citing papers authored by Zhongli Cai

Since Specialization

Citations

This map shows the geographic impact of Zhongli Cai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhongli Cai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhongli Cai more than expected).

Fields of papers citing papers by Zhongli Cai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhongli Cai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhongli Cai. The network helps show where Zhongli Cai may publish in the future.

Co-authorship network of co-authors of Zhongli Cai

This figure shows the co-authorship network connecting the top 25 collaborators of Zhongli Cai. A scholar is included among the top collaborators of Zhongli Cai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhongli Cai. Zhongli Cai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preclinical Comparison of [ ¹¹¹ In]In- and [ ²²⁵ Ac]Ac-DOTA-Trastuzumab IgG, F(ab′) ₂ and Fab for Theranostic SPECT/CT Imaging and α-Particle Radioimmunotherapy of HER2-Positive Human Breast Cancer 2024 ·Molecular Pharmaceutics ·(unknown), Zhongli Cai, Conrad Chan, (unknown), Raymond M. Reilly	1
2	[225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts 2023 ·EJNMMI Radiopharmacy and Chemistry ·(unknown), Zhongli Cai, Conrad Chan, (unknown), Raymond M. Reilly	8
3	Adjuvant Auger Electron-Emitting Radioimmunotherapy with [¹¹¹In]In-DOTA-Panitumumab in a Mouse Model of Local Recurrence and Metastatic Progression of Human Triple-Negative Breast Cancer 2023 ·Molecular Pharmaceutics ·(unknown), Zhongli Cai, (unknown), (unknown), Raymond M. Reilly	3
4	Panitumumab-DOTA-¹¹¹In: An Epidermal Growth Factor Receptor Targeted Theranostic for SPECT/CT Imaging and Meitner–Auger Electron Radioimmunotherapy of Triple-Negative Breast Cancer 2022 ·Molecular Pharmaceutics ·(unknown), Zhongli Cai, (unknown), Raymond M. Reilly	7
5	Tumor uptake and tumor/blood ratios for [89Zr]Zr-DFO-trastuzumab-DM1 on microPET/CT images in NOD/SCID mice with human breast cancer xenografts are directly correlated with HER2 expression and response to trastuzumab-DM1 2018 ·Nuclear Medicine and Biology ·(unknown), Zhongli Cai, Raymond M. Reilly	13
6	Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with 177Lu 2016 ·Pharmaceutical Research ·Zhongli Cai, Simmyung Yook, Yijie Lu, (unknown), Mitchell A. Winnik, Jean‐Philippe Pignol, Raymond M. Reilly	53
7	Monte Carlo N-Particle (MCNP) Modeling of the Cellular Dosimetry of⁶⁴Cu: Comparison with MIRDcell S Values and Implications for Studies of Its Cytotoxic Effects 2016 ·Journal of Nuclear Medicine ·Zhongli Cai, (unknown), Raymond M. Reilly	31
8	Intracellular Routing in Breast Cancer Cells of Streptavidin-Conjugated Trastuzumab Fab Fragments Linked to Biotinylated Doxorubicin-Functionalized Metal Chelating Polymers 2014 ·Biomacromolecules ·(unknown), Zhongli Cai, Jae‐Wook Kang, Amanda J. Boyle, Jarrett Adams, Yijie Lu, (unknown), Sachdev S. Sidhu, Raymond M. Reilly, Mitchell A. Winnik	18
9	Trastuzumab Labeled to High Specific Activity with 111In by Conjugation to G4 PAMAM Dendrimers Derivatized with Multiple DTPA Chelators Exhibits Increased Cytotoxic Potency on HER2-Positive Breast Cancer Cells 2013 ·Pharmaceutical Research ·Conrad Chan, Zhongli Cai, Raymond M. Reilly	23
10	Investigation of the effects of cell model and subcellular location of gold nanoparticles on nuclear dose enhancement factors using Monte Carlo simulation 2013 ·Medical Physics ·Zhongli Cai, Jean‐Philippe Pignol, Niladri Chattopadhyay, (unknown), Eli Lechtman, Raymond M. Reilly	30
11	Role of Antibody-Mediated Tumor Targeting and Route of Administration in Nanoparticle Tumor Accumulation in Vivo 2012 ·Molecular Pharmaceutics ·Niladri Chattopadhyay, Humphrey Fonge, Zhongli Cai, Deborah A. Scollard, Eli Lechtman, Susan J. Done, Jean‐Philippe Pignol, Raymond M. Reilly	82
12	Implications on clinical scenario of gold nanoparticle radiosensitization in regards to photon energy, nanoparticle size, concentration and location 2011 ·Physics in Medicine and Biology ·Eli Lechtman, Niladri Chattopadhyay, Zhongli Cai, Shahram Mashouf, Raymond M. Reilly, Jean‐Philippe Pignol	209
13	Cellular Dosimetry of ¹¹¹In Using Monte Carlo N-Particle Computer Code: Comparison with Analytic Methods and Correlation with In Vitro Cytotoxicity 2010 ·Journal of Nuclear Medicine ·Zhongli Cai, Jean‐Philippe Pignol, Conrad Chan, Raymond M. Reilly	54
14	Design and Characterization of HER-2-Targeted Gold Nanoparticles for Enhanced X-radiation Treatment of Locally Advanced Breast Cancer 2010 ·Molecular Pharmaceutics ·Niladri Chattopadhyay, Zhongli Cai, Jean‐Philippe Pignol, Brian Keller, Eli Lechtman, Reina Bendayan, Raymond M. Reilly	99
15	Micro-SPECT/CT with ¹¹¹In-DTPA-Pertuzumab Sensitively Detects Trastuzumab-Mediated HER2 Downregulation and Tumor Response in Athymic Mice Bearing MDA-MB-361 Human Breast Cancer Xenografts 2009 ·Journal of Nuclear Medicine ·Kristin McLarty, Bart Cornelissen, Zhongli Cai, Deborah A. Scollard, Danny L. Costantini, Susan J. Done, Raymond M. Reilly	58
16	Computational analysis of the number, area and density of γ-H2AX foci in breast cancer cells exposed to¹¹¹In-DTPA-hEGF or γ-rays using Image-J software 2009 ·International Journal of Radiation Biology ·Zhongli Cai, Katherine A. Vallis, Raymond M. Reilly	72
17	Relationship Between Induction of Phosphorylated H2AX and Survival in Breast Cancer Cells Exposed to ¹¹¹In-DTPA-hEGF 2008 ·Journal of Nuclear Medicine ·Zhongli Cai, Zhuo Chen, (unknown), Deborah A. Scollard, Raymond M. Reilly, Katherine A. Vallis	50
18	Epidermal Growth Factor Receptor Inhibition Modulates the Nuclear Localization and Cytotoxicity of the Auger Electron Emitting Radiopharmaceutical 111In-DTPA Human Epidermal Growth Factor 2007 ·Journal of Nuclear Medicine ·(unknown), (unknown), Zhongli Cai, Deborah A. Scollard, Zhuo Chen, Raymond M. Reilly, Katherine A. Vallis	31
19	111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer 2007 ·Journal of Nuclear Medicine ·(unknown), Conrad Chan, Zhongli Cai, Katherine A. Vallis, Raymond M. Reilly	148
20	The renal cell carcinoma lysis by a specific cytotoxic T cell clone is independent of the Fas/Fas‐L cytotoxic pathway 1996 ·Tissue Antigens ·Anne Caignard, (unknown), Zhongli Cai, Carine Asselin‐Paturel, (unknown), Salem Chouaı̈b	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact